A molecule called OLE may help the brain’s immune cells fight Alzheimer’s disease by containing toxic plaques, according to a study published in Cell Death and Disease. Researchers found that the compound, derived from the PM20D1 gene, restores the protective function of microglia—the immune cells that normally clear harmful beta-amyloid deposits.
Related: Health Plans for Family and Senior Citizens: One Plan or Separate?
In Alzheimer’s, microglia lose their ability to remove these plaques, which then damage neurons. The study showed that OLE helps microglia encase the plaques, reducing their size and toxicity. In animal tests, the treatment improved memory performance and limited the plaques’ interaction with brain cells. The protective effect was visually confirmed through imaging, where microglia marked in red were observed forming barriers around amyloid plaques in blue, shielding nearby neurons stained green.
“One of the most significant findings is that we’ve identified a molecule capable of restoring microglia’s protective function,” said Sánchez Mut, who leads the Functional Epi-Genomics of Aging and Alzheimer’s Disease lab at the Instituto de Neurociencias CSIC-UMH. The work suggests the damage caused by impaired microglia can be reversed, opening new therapeutic possibilities. The reversal of microglial impairment was a key focus, as these cells not only fail to clear plaques but also contribute to neuronal damage as the disease advances.
Related: The science behind DNA paternity testing
The study’s findings are protected by two European patents, one held by the CSIC. Funding came from multiple sources, including the Dementia Research Switzerland – Synapsis Foundation, the Pasqual Maragall Foundation, and the European Research Council, among others. Additional support was provided by the Swiss National Science Foundation, the École Polytechnique Fédérale de Lausanne (EPFL), the Spanish Ministry of Science, Innovation and Universities, the Severo Ochoa Centres of Excellence programme, the Prometeo programme of the Generalitat Valenciana, the European Regional Development Fund (ERDF), the National Research Foundation of Korea (NRF), and the European Social Fund (ESF+).
Related: High-Resolution PET Scanner Detects Early Brain Disease Signs
Alzheimer’s is marked by the accumulation of beta-amyloid plaques and the deterioration of microglia. As the disease progresses, these immune cells fail to clear the toxic buildup, accelerating neuronal damage. The study’s approach targets this breakdown directly by restoring microglial function, potentially counteracting the disease’s progression at a cellular level. The translational potential of OLE is further supported by its patented status and the breadth of interdisciplinary funding behind the research.